

To: [REDACTED] [REDACTED] [REDACTED] @bpo.nl]
Cc: [REDACTED] [REDACTED] [REDACTED] @minvws.nl]; [REDACTED] [REDACTED] @dsm.com]; [REDACTED] [REDACTED] [REDACTED] @minvws.nl]; [REDACTED] [REDACTED] @roche.com]; [REDACTED] [REDACTED] @roche.com]
From: [REDACTED] [REDACTED]
Sent: Mon 4/6/2020 2:14:43 PM
Subject: Re: limited license agreement
Received: Mon 4/6/2020 2:15:10 PM

Thanks, [REDACTED]. The fact that there are third party manufacturers involved is new to me, but no worries, we get this resolved quickly. One question: Do you already know that the manufacturing will be limited to those two companies? Or do you expect that there will be more?

Regards, [REDACTED]

[REDACTED] 5.1.2e

Roche Diagnostics International Ltd
Forrenstrasse 2
6343 Rotkreuz
Switzerland

Tel: +41 [REDACTED]
e-mail: [REDACTED] @roche.com
www.roche.ch/rotkreuz

Note: This message is intended only for the use of the named recipient(s) and may contain confidential and/or proprietary information. If you are not the intended recipient, please contact the sender and delete this message. Any unauthorized use of the information contained in this message is prohibited.

On Mon, Apr 6, 2020 at 3:38 PM [REDACTED] [REDACTED] <[REDACTED]@bpo.nl> wrote:

Dear [REDACTED]

Regarding the agreement please find attached our remarks.

Met vriendelijke groet,

Mit freundlichen Grüßen,

With kind regards,

[REDACTED] [REDACTED] [REDACTED]

[REDACTED] 5.1.2e



BPO Nederland bv
Scheepmakerij 11
2628 AA Delft
the Netherlands

T. +31 (0) 15 362 0000
D. +31 (0) 15 362 0001
E. [REDACTED] @bpo.nl
W. www.bpo.nl/

